These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9247503)

  • 1. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
    Shapiro SM; Oudiz RJ; Cao T; Romano MA; Beckmann XJ; Georgiou D; Mandayam S; Ginzton LE; Brundage BH
    J Am Coll Cardiol; 1997 Aug; 30(2):343-9. PubMed ID: 9247503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study on long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol infusion].
    Cao TS; Yuan LJ; Duan YY; Wang ZJ; Zhuang L; Shapiro SM; Brundage BH
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):106-9. PubMed ID: 12783707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
    Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
    J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
    Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
    Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
    McLaughlin VV; Shillington A; Rich S
    Circulation; 2002 Sep; 106(12):1477-82. PubMed ID: 12234951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
    Aguilar RV; Farber HW
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.
    Wax D; Garofano R; Barst RJ
    Chest; 1999 Oct; 116(4):914-20. PubMed ID: 10531153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.
    Strange C; Bolster M; Mazur J; Taylor M; Gossage JR; Silver R
    Chest; 2000 Oct; 118(4):1077-82. PubMed ID: 11035680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
    Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
    J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
    Humbert M; Sanchez O; Fartoukh M; Jagot JL; Le Gall C; Sitbon O; Parent F; Simonneau G
    Eur Respir J; 1999 Jun; 13(6):1351-6. PubMed ID: 10445611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension.
    Ting H; Sun XG; Chuang ML; Lewis DA; Hansen JE; Wasserman K
    Chest; 2001 Mar; 119(3):824-32. PubMed ID: 11243964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
    Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
    Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoprostenol treatment in children with severe pulmonary hypertension.
    Lammers AE; Hislop AA; Flynn Y; Haworth SG
    Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
    Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
    Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
    Frost AE; Quiñones MA; Zoghbi WA; Noon GP
    J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic management of primary pulmonary hypertension].
    Chaouat A; Weitzenblum E
    Presse Med; 2002 Feb; 31(7):320-8. PubMed ID: 11899690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term epoprostenol therapy in pulmonary artery hypertension.
    Sakuma M; Demachi J; Nawata J; Suzuki J; Takahashi T; Shirato K
    Circ J; 2009 Mar; 73(3):523-9. PubMed ID: 19179773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.